At a glance
- Originator Toa Eiyo
- Developer Toa Eiyo; Yamasa Corporation
- Class Anti-ischaemics; Antihypertensives; Vasodilators
- Mechanism of Action Adenosine A2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glaucoma; Reperfusion injury
- Discontinued Hypertension
Most Recent Events
- 16 Nov 2010 No development reported - Preclinical for Glaucoma in Japan (Ophthalmic)
- 16 Nov 2010 No development reported - Preclinical for Reperfusion injury in Japan (IV)
- 31 Jan 2008 Preclinical development is ongoing